Biotech company Polaryx Therapeutics reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for Investigational New Drug Application (IND) of PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL or CLN3).
JNCL or CLN3 is reportedly a rare and fatal genetic lysosomal storage disorder caused by a Cln3 gene mutation. CLN3 patients suffer from vision loss leading to blindness, seizures, progressive neurological deterioration, severe motor and cognitive declines and eventually death.
The company said PLX-200 is a repurposed drug that binds to the retinoid X receptor-α (RXRα), which binds to PPARα thereby up-regulating the expression of TPP1 mRNA in brain cells via the PPARα/RXRα heterodimer. PLX-200 activates PPARα, which enhances production of transcription factor EB (TFEB) in brain cells. PLX-200 also reduces inflammation and preventing cell death (apoptosis).
No drug is currently available to halt and/or delay the progression of the disease, concluded the company.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT